

Science has the power to cure, but no single organization can do it alone. We partner with world-class organizations to tackle the most pressing health challenges



NIH & OTHER
GOVERNMENT AGENCIES



LIFE SCIENCES COMPANIES
& ACADEMIA



FOUNDATIONS &
PATIENT ORGANIZATIONS

Foundation for the National Institutes of Health Building Bridges to Breakthroughs

OUR WORK

- We accelerate new therapies, diagnostics, and potential cures
- We advance global health
- We power science and help train the next generation of scientists

\$1.6B

private funds raised

122


active partnerships

\$0.85

of every dollar directly
supports programs

THE FNIH IS AN INDEPENDENT 501(C)(3) NONPROFIT ORGANIZATION
FOUNDED BY THE U.S. CONGRESS TO SUPPORT THE MISSION OF THE NIH

FNIH has a long legacy of impactful work in Alzheimer's



Plasma Aβ project has produced numerous scientific impacts

Extremely valuable dataset for studying plasma biomarkers of Alzheimer's disease, used by **many** other studies

Use of plasma biomarkers to predict the onset of Alzheimer's symptoms, which may help to design prevention trials and lead to personalized prediction of risk for symptomatic AD


Head-to-head comparison of leading blood tests

Understanding the timing of biomarker changes

Exploration of the complex, non-linear relationships between biomarkers

BC Plasma Abeta

AMP AD: Transforming Alzheimer's research through open science




Results and accomplishments

- Generated rich, human, multiomic data, which has been made **available to >3000 users** to date (60% academia / 40% industry)
- Established **new mechanistic disease insights** on role of the genome, proteome, metabolome, and microbiome
- Increased the availability of **molecular network models** of disease pathways
- Developed **phenotype animal models** and evaluated them relative to human molecular networks
- Identified and ranked **900+ unique targets**, and made them available through **the Agora Platform**, along with supporting evidence and extensive druggability information
- Confirmed the utility of **Tau PET imaging for tracking** responsiveness to treatment and disease progression
- Data and biosamples from the **A4 study are now available for download** and exploration

Infrastructure for disseminating data and knowledge


AMP AD data has influenced open science practices



AD Knowledge Portal
Catalog of data and tools



adknowledgeportal.org




Agora
• AD target nominations
• Target-specific resources and results



agora.adknowledgeportal.org

1400+ publications
referencing the AD Knowledge Portal



- Data contributors as authors
- Secondary data users as authors

Imaging AD biomarker - SV2A

This project seeks to validate using PET scans to trace the synaptic vesicle glycoprotein 2A as a reliable biomarker to measure the progression of Alzheimer's disease and the effectiveness of potential treatments

BC SV2A

AD Biosignature is the next phase of BBMx work

- Launched July 2025
- 5 industry partners, 1 nonprofit, 1 in-kind
- \$4.25M raised

Goal: Develop a prognostic biosignature for clinical progression in amyloid positive individuals who are initially **cognitively unimpaired** or have **mild cognitive impairment (MCI)**

BC AD BS

FNIH has managed AD projects totaling over half a billion dollars


ADNI 1, ADNI Go,
ADNI 2, and ADNI 3
(2004-2022)
\$206M

AMP AD 1.0
(2014)
\$225.2M

AMP AD 2.0
(2023)
\$80.2M

Biomarkers
Consortium
Alzheimer's Disease
Projects
(2006-present)
\$18.4M

Contact



Francesca Cignarella, PhD, PMP
Senior Project Manager,
Translational Science, Neuroscience
fcignarella@fnihi.org



Sri Pullagura, PhD
Program Manager,
Translational Science, Neuroscience
spullagura@fnihi.org



Liz Mesmer
Strategic Alliances Officer
Strategic Alliances and Advancement
lmesmer@fnihi.org



www.fnihi.org